Wegovy, Ozempic exclusivity challenges denied by US patent appeal board

The US Patent and Trade­mark Of­fice’s Patent Tri­al and Ap­peal Board has de­clined to re­view two patent chal­lenges around No­vo Nordisk’s semaglu­tide brought by gener­ics mak­er My­lan Phar­ma­ceu­ti­cals.

My­lan, now part of Vi­a­tris, pe­ti­tioned the PTO to re­view key patents pro­tect­ing semaglu­tide, the ac­tive in­gre­di­ent in No­vo Nordisk’s GLP-1 type 2 di­a­betes block­buster Ozem­pic and weight loss drug We­govy. Vi­a­tris re­port­ed in its re­cent sec­ond quar­ter earn­ings pre­sen­ta­tion that its gener­ic ver­sions for both Ozem­pic and We­govy were un­der reg­u­la­to­ry re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.